A share price of Standard BioTools Inc [LAB] is currently trading at $1.18, down -0.84%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LAB shares have gain 3.51% over the last week, with a monthly amount drifted -9.92%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Standard BioTools Inc [NASDAQ: LAB] stock has seen the most recent analyst activity on August 13, 2025, when TD Cowen downgraded its rating to a Hold but kept the price target unchanged to $1.55 for it. Previously, KeyBanc Capital Markets downgraded its rating to Sector Weight on February 27, 2025. On April 16, 2024, TD Cowen initiated with a Buy rating and assigned a price target of $3.50 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $3.25 on April 04, 2024. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $4 as its price target on July 12, 2023.
Standard BioTools Inc experienced fluctuations in its stock price throughout the past year between $0.92 and $2.25. Currently, Wall Street analysts expect the stock to reach $3.25 within the next 12 months. Standard BioTools Inc [NASDAQ: LAB] shares were valued at $1.18 at the most recent close of the market. An investor can expect a potential return of 175.42% based on the average LAB price forecast.
Analyzing the LAB fundamentals
Trailing Twelve Months sales for Standard BioTools Inc [NASDAQ:LAB] were 128.83M which represents -56.52% decline. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -0.97%, Pretax Profit Margin comes in at -0.86%, and Net Profit Margin reading is -1.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.29 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1667 points at the first support level, and at 1.1533 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2017, and for the 2nd resistance point, it is at 1.2233.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Standard BioTools Inc [NASDAQ:LAB] is 4.38. As well, the Quick Ratio is 4.14, while the Cash Ratio is 1.2. Considering the valuation of this stock, the price to sales ratio is 3.52, the price to book ratio is 1.13.
Transactions by insiders
Recent insider trading involved Casdin Partners Master Fund, L, Director, that happened on Nov 12 ’25 when 0.38 million shares were purchased. Director, Casdin Partners Master Fund, L completed a deal on Nov 11 ’25 to buy 0.3 million shares. Meanwhile, Director Casdin Partners Master Fund, L bought 0.28 million shares on Nov 10 ’25.
